:

Department of Research Programs > ResearchProtocols
 
Department of Research Programs


To be eligible to enroll in a study you MUST be enrolled as a DEERS-eligible service member, dependent, retiree, or DOD civilian.

For contact information regarding protocols that may interest you, click on the individual links on the left.
Seeking Patients with Asymptomatic Smoldering Multiple Myeloma for Lenalidomide Test Trial
Official Title:ECOG 3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple Myeloma
Date Window: 11/21/2012 - 11/21/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:To test how well lenalidomide works to treat asymptomatic smoldering multiple

ClinicalTrials.gov identifier
NCT01169337


Official Title:ECOG 2906: Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos
Date Window: 11/26/2012 - 11/26/2017
Contact for Details:Brenda Davis, RN 301-319-2367 or Ketly Bateau-Walker, RN 310-295-4374
Summary:
To compare the effectiveness of clofarabine to standard induction chemotherapy, and to test the effectiveness of decitabine as maintenance therapy, in patients over age 60 with acute myelogenous leukemia.

ClinicalTrials.gov identifier
NCT01041703


Help your fellow service members and veterans!
Official Title:Exploring the Natural History of Traumatic Brain Injury within a Military Cohort – A Longitudinal Database and Blood Banking Study
Date Window: 4/26/2013 - 4/1/2028
Contact for Details:For more information please call 855-753-3394 or email natural.history1@dvbic.org
Summary:​​If you served in the military after October 2001, you may be eligible to participate in a reserach study requested by Congress. We are currently recruiting service members and veterans who 1) have incurred a TBI since 2001, 2) incurred a bodily injury that was not a TBI since 2011 or 3) have served at any point since 2001 but were not injured.

The purpose of the study is to increase our understanding of the long term effects of trumatic brain injury on service members and veterans. Participation will include short yearly appointments. Each visit will last either 2 hours or 2 days and will occure once per year for up to 15 years. You may elect to participate only in web-based and telephone measures. 

Your participant could contribute to knowledge that could improve the care of your fellow service members and veterans. You may be compensated for your participation.


Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Subjects With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
Official Title:GOG 0241: A CGIC Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/-NCI Supplied Agent: Bevacizumab Compared with Oxaliplatin & Capecitabine +/- Bevacizumab as 1st Line Chemo in subj w/Mucinous Epithelial Ovarian or Fallop
Date Window: 6/13/2013 - 12/20/2017
Contact for Details:Karen Harrington; karen.m.harrington.civ@health.mil
Summary:

Proton Radiation Therapy for Low Risk and Low-Intermediate Risk Cancer of the Prostate
Official Title:A Trial of Proton Radiation Therapy Using Standard Fractionation for Low Risk and Low-Intermediate Risk Adenocarcinoma of the Prostate
Date Window: 11/30/2010 - 11/30/2020
Contact for Details:Jean Petrov, RN MS (301) 295-5010; Kathleen Noel, RN MS (301) 400-0507
Summary:The purpose is to determine the toxicities, safety of the proton radiation therapy and the quality of life with proton therapy in the treatment of low risk and low-intermediate risk adenocarcinoma of the prostate.

http://www.Clinitical Trials.gov (NCT01045226)


GOG 0263
Official Title:GOG 0263: Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Date Window: 9/18/2013 - 9/18/2018
Contact for Details:Karen Harrington, karen.m.harrington.civ@health.mil
Summary:This randomized phase III trial is studying giving radiation therapy together with chemotherapy to see how well it works compared to radiation therapy alone in treating patients with stage I or stage II cervical cancer who previously underwent surgery.

Active Comparator: Arm I: Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5½ weeks.

 

Experimental: Arm II: Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 weeks in the absence of disease progression or unacceptable toxicity.


GOG 0274
Official Title:GOG 0274: Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Date Window: 9/18/2013 - 9/18/2018
Contact for Details:Karen Harrington (karen.m.harrington.civ@health.mil)
Summary:This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with locally advanced cervical cancer.

Active Comparator: Arm I: Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.

Experimental: Arm II: Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.


GOG 0261
Official Title:GOG 0261: Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer
Date Window: 9/18/2013 - 9/18/2018
Contact for Details:Karen Harrington (karen.m.harrington.civ@health.mil)
Summary:This randomized phase III trial is studying giving paclitaxel together with carboplatin to see how well it works compared with giving paclitaxel together with ifosfamide in treating patients with newly diagnosed persistent or recurrent uterine or ovarian cancer.

Experimental: Arm I:  Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1.

Experimental: Arm II:  Patients receive paclitaxel as in arm I and ifosfamide IV over 1 hour on days 1-3.


Proton Therapy in Larger Doses/Fewer Treatments for Low and Intermediate Risk Cancer of the Prostate
Official Title:A Trial of Proton Radiation Therapy or Intensity Modulated Radiation Therapy Using MildHypofractionation for Low and Intermediate-Risk Adenocarcinoma of the Prostate
Date Window: 5/30/2012 - 5/30/2020
Contact for Details:Jean Petrov, RN MS (301) 295-5010; Kathleen Noel, RN MS (301) 400-0507
Summary:The purpose is to determine toxicities, freedom from failure, safety of the proton radiation therapy treatment and the quality of life with proton therapy in the treatment of low and intermediate-risk adenocarcinoma of the prostate.

http://www.ClinicalTrials.gov (NCT01352429)


GOG 0258
Official Title:GOG 258: Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Date Window: 9/18/2013 - 9/19/2018
Contact for Details:Karen Harrington (karen.m.harrington.civ@health.mil)
Summary:This randomized phase III trial is studying carboplatin and paclitaxel to see how well they work when given with or without cisplatin and radiation therapy in treating patients with stage I, stage II, stage III, or stage IVA endometrial cancer.

Experimental: Arm I:  Patients receive cisplatin IV on days 1 and 29. Patients also undergo external-beam radiotherapy once daily, 5 days a week, for 5-6 weeks. Some patients may then undergo brachytherapy over 2-3 weeks. Beginning within 8 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
 
Experimental: Arm II:  Patient receive paclitaxel IV over 3 hours and carboplatin IV on day 1.  Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
 
 


Contact

Location
Building 17B
3rd Floor, Suite E

Phone
Main (301) 295-8239/8219

Hours of Operation
Monday thru Friday
0700 - 1630